MAGE-3 (281-295)

MAGE-3 (281-295) is a synthetic peptide derived from the melanoma-associated antigen 3 (MAGE-3) protein, encompassing amino acid residues 281 to 295. As a member of the cancer-testis antigen family, MAGE-3 is recognized for its restricted expression in various malignancies and its immunogenic properties, making it a valuable target in tumor immunology research. The 281-295 fragment represents a well-characterized epitope region, frequently utilized in studies exploring antigen presentation, T cell recognition, and the molecular mechanisms underlying tumor immune surveillance. Its defined sequence and high specificity have established it as a versatile reagent for investigating peptide-MHC interactions and for developing experimental models in immunological assays.

Epitope mapping: In immunology research, the 281-295 region of MAGE-3 is extensively employed for epitope mapping studies. By using this synthetic peptide, researchers can precisely delineate the antigenic determinants recognized by cytotoxic T lymphocytes (CTLs) in the context of various major histocompatibility complex (MHC) molecules. This enables fine-scale analysis of T cell epitopes, aiding in the identification of immunodominant regions within the MAGE-3 protein and providing critical insights into antigen-specific immune responses in cancer models.

T cell activation assays: The peptide is routinely used to stimulate antigen-specific T cells in vitro, serving as a defined stimulus in functional assays such as ELISPOT, intracellular cytokine staining, and cytotoxicity assays. Through these applications, investigators can assess T cell activation, cytokine production, and effector function in response to MAGE-3-derived antigens. Such assays are instrumental in evaluating the immunogenicity of candidate epitopes and in characterizing T cell repertoires in both basic and translational research settings.

Peptide-MHC binding studies: MAGE-3 (281-295) serves as a model ligand in peptide-MHC binding affinity experiments. By incorporating this peptide into binding assays, researchers can quantitatively assess its interaction with specific HLA alleles, elucidating the structural and biochemical parameters that govern peptide presentation. These studies contribute to the broader understanding of antigen processing and presentation, informing the rational design of immunotherapeutic strategies and peptide-based vaccines.

Antigen processing research: The defined sequence of the 281-295 peptide allows for controlled investigations into the mechanisms of antigen processing and presentation by professional antigen-presenting cells (APCs). By tracking its uptake, processing, and subsequent presentation on MHC class I molecules, researchers can dissect the cellular pathways involved in cross-presentation and immune recognition of tumor-associated antigens. Such studies are essential for elucidating the molecular underpinnings of tumor immune evasion and for optimizing strategies to enhance antigen presentation in experimental systems.

Tool for immunogenicity screening: The peptide is also utilized as a reference antigen in immunogenicity screening protocols, enabling comparative evaluation of immune responses elicited by different peptide sequences or antigen formulations. By serving as a benchmark in these assays, it facilitates the identification of novel immunogenic epitopes and supports the preclinical assessment of peptide-based immunomodulatory agents. Its well-characterized immunological profile provides a reliable foundation for the development and validation of new research tools in tumor immunology and antigen discovery.

1. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

2. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis

3. Identification, Localization in the Central Nervous System and Novel Myostimulatory Effect of Allatostatins in Tenebrio molitor Beetle

4. The effect of sex on immune responses to a homocitrullinated peptide in the DR4-transgenic mouse model of Rheumatoid Arthritis

5. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum